DBV Technologies | DBVT - Interest Expense On Debt


DBV Technologies reported $461K in Interest Expense on Debt for its fiscal quarter ending in March of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Alnylam Pharmaceuticals USD 82.05M 12.76M Jun/2026
Amarin USD 3K 5K Dec/2024
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
DBV Technologies USD 461K 323.71K Mar/2025
Galectin Therapeutics USD 1.27M 220K Jun/2024
Halozyme Therapeutics USD 5.51M 597K Mar/2026
Incyte USD 582K 13K Jun/2026
Insmed USD 20.08M 517K Mar/2026
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Sarepta Therapeutics USD 20.84M 13.28M Dec/2025
Ultragenyx Pharmaceutical USD 22M 1000K Jun/2026
United Therapeutics USD 3.1M 100K Dec/2025